Congenital hyperinsulinism of the newborn: a case report

Hiperinsulinismo congénito del recién nacido. A propósito de un caso clínico

Josefina Sáez, Juan Carlos Pattillo, Pilar Orellana, Claudia Godoy

A General Surgery Resident, Faculty of Medicine, Pontificia Universidad Católica de Chile
B Pediatric Surgery, Division of Surgery, Faculty of Medicine, Pontificia Universidad Católica de Chile
C Nuclear Medicine, Radiology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile
D Pediatric Endocrinology, Division of Pediatrics, Faculty of Medicine, Pontificia Universidad Católica de Chile

Received: 27-4-2016; Accepted: 17-12-2016

Abstract

Congenital hyperinsulinism (HC) is the most frequent cause of persistent hypoglycemia in the newborn and it is characterized by an inappropriately elevated insulin level in presence of hypoglycemia. Initial management is medical treatment, but if it fails, partial pancreatectomy is the surgical procedure of choice. Objective: To report a case of a newborn with CH to aware on this condition and update its multidisciplinary management. Case report: The case of a full term newborn with severe symptomatic hypoglycemia unresponsive to medical treatment is reported. Ultrasonography and abdominal MRI were normal, Gallium 68 PET/CT showed uptake in the body of the pancreas. Laparoscopic corporocaudal pancreatectomy was performed. The patient resolved hypoglycemia and was discharged without incidents. Genetic study was consistent with focal CH, confirmed later by biopsy. Discussion: This case report exposes the clinical presentation of CH and its diagnosis. It emphasizes on the surgical treatment and the advantages of minimally invasive technique.

Introduction

Congenital hyperinsulinism (HC) is the main cause of persistent and recurrent hypoglycemia in the first year of life. Its incidence ranges from 1/27,000 to 1/50,000 in newborns. Laidlaw described it in 1938 and called it ‘Ne-sidioblastosis’. It is currently described as a heterogeneous condition in clinical presentation, genetics, histology and response to treatment.

HC is characterized by inadequate and unregulated insulin production when blood glucose levels are low. Insulin secretion by pancreatic β cells is controlled to maintain fasting glucose normally between 63 and 99 mg/dl.

The importance of early diagnosis and treatment lies in neurological damage secondary to hypoglycemic states, which may be permanent. Management requires metabolic stabilization with glucose supply and decrease insulin secretion, which is mainly achieved with diazoxide or somatostatin analogues (Octreotide). If glycemic control is not steady with medical mana-
glement, surgical treatment should be considered\footnote{16}. In order to plan the surgery, it is important to know if the lesion that produces HC is histologically diffuse, focal or atypical\footnote{6}. For this reason, genetic and/or imaging study is useful, as Fluorine 18-L-3,4 Dihydroxyphenylalanine Positron Emission Tomography (18F-DOPA-PET/CT scan)\footnote{12,13}. If the lesion is diffuse, the surgery of choice is subtotal pancreatectomy. However, if this is focalized, a resection of the lesion will be preferred\footnote{13,14}. Along with the progress of the minimally invasive technique, laparoscopic surgery became an effective and safe alternative in the pediatric population\footnote{15}. In our country there are reports of the use of this technique in pancreatic pathology in children\footnote{16,17}. However, according to our search, it would not be described as an option for HC cases in newborns.

The objective of this article is to report a case of focalized HC, which was successfully treated with minimally invasive surgery, and also to discuss its multidisciplinary confrontation.

**Clinical case**

39 week-old male newborn, birth weight 4,255 g and length 53.5 cm. He is the second son of healthy non-consanguineous parents with a 3-year-old healthy sister. The mother underwent pregnancy with fasting hyperglycemia managed with diet (glycosylated HbA1c 4.9\%). Cesarean delivery due to fetal dystocia was performed. He did not present any congenital anomalies or physical dysmorphia. His capillary glycemia at 2 hours of life was normal.

At 17 hours of life, he presented drowsiness, hypotonia, respiratory distress and weak suction. Glycemia 28 mg/dl, Insulin 30 IU/L (N.V. suppressed) and Cortisol 10.9 μg/dl (N.V. > 18). The second sample showed glycemia levels of 33 mg/dl, Insulin 23 IU/L and negative ketonemia, which confirmed HC. He required intravenous glucose up to 17 mg/kg/min, and intravenous Hydrocortisone at an initial dose of 50 mg/m\(^2\)/day. On the fifth day oral Diazoxide was started progressively from 5 to 20 mg/kg/day and Hydrochlorothiazide 2 mg/kg/day, without effective response. At 20 days of life, Octreotide was started with a dose up to 30 μg/kg/per day (initially in continuous intravenous infusion and then subcutaneous infusion every 6 hours). Intravenous Glucagon was added (5μg/ kg/hour). With this, glucose requirements decreased to 4 mg/kg/min without achieving normoglycemia.

Ultrasound and MRI of the abdomen were normal. PET/CT with Gallium 68 reported focal area of overexpression of somatostatin receptors at the body-tail union of the pancreas (figure 1).

The genetic study of hyperinsulinism at the Wellcome Wolfson Medical Research Center, University of Exeter Medical School, UK, revealed a heterozygous missense mutation in the exon 35 gene of the ABCC8 gene, p.Ser1423Pro inherited from the father, asymptomatic carrier, while maternal genetic study was normal.

Clinical manifestations, the genetic study and the PET/CT image allowed us to conclude that the HC corresponded to a focal pancreatic lesion.

A laparoscopic corpurocaudal pancreatectomy was planned and performed at 37 days of life. The abdomen was accessed in supine position through an infraumbilical incision, with open technique. A CO\(_2\) heater was used with 10mmHg of pressure with a maximum flow of 3 lpm. Two 5 mm trocars were used, one for access and other in the left iliac fossa for coagulation instruments, plus two 3 mm instruments inserted percutaneously into the abdomen. The dissection was initiated by accessing the lesser sac, being aware of the gastroepiploic vessels. The stomach was sutured to the anterior abdominal wall, achieving optimal visualization of the pancreas. The release of the splenic angle of the colon allowed access to the splenic hilum and tail of the pancreas. With the use of monopolar and bipolar coagulation and Ligasure (R), the pancreas was separated from the branches of the splenic vein from the tail to the body. A nodular lesion of increased consistency was identified, very attached to the splenic vein (figure 2). Proximal dissection allowed the identification of the superior mesenteric vein, the portal vein and the hepatic artery. A retropancreatic tunnel was opened; the pancreas was sectioned and ligated with Endoloop (R). During separation of the splenic vein tumor, patient started to bleed, requiring ligation of the splenic vessels with Hemolock (R) to achieve hemostasis. The pancreas was removed by the umbilical wound and no drainage was used. At the end, the spleen was moderately ischemic without engorgement.

The biopsy described pancreatic tissue of partially distorted architecture, with irregular aggregates of islets of Langerhans mixed with ductoinsular complexes, delimited with immunohistochemistry of neuroendocrine markers (chromogranin, synaptophysin, CD56). The rest of the sample reported preserved morphology, neuroendocrine cells dispersed positive in immunohistochemistry mentioned, and that did not conform a lesion.

The patient progressed favorably, rapidly achieving normal glycemia without medication and was discharged 10 days after surgery.

At 18 months of age, he remains eutrophic, normoglycemic and has normal psychomotor development. Ultrasonography shows spleen of normal size and perfusion.
Congenital hyperinsulinism - J. Sáez et al

**Discussion**

HC is an uncommon disorder of glucose metabolism, which is the most common cause of persistent hypoglycemia of the newborn. Its pathogenesis lies in excessive production of insulin by pancreatic β cells, even with low blood glucose levels.

The diagnosis is suspected in cases of persistent hypoglycemia or poor tolerance to fasting (< 1 hr), unresponsive to oral intake, and requiring very high glucose loads (> 8 mg/K/min). They are usually macrosomic newborns, but they have been reported with normal weight or even small.

Symptoms may be mild and nonspecific (lethargy, poor sucking, irritability) or even severe, such as apnea, seizures and loss of consciousness (coma).

Insulin and C-peptide levels are inappropriately elevated compared to hypoglycemia. In addition, low levels of free fatty acids and ketones can be observed by inhibition of lipolysis. This increases the risk of brain injury. The favorable response to Glucagon and somatostatin analogs also is an indicator.

It is possible to find low levels of cortisol in relation to hypoglycemia in neonates with HC, corresponding to an inappropriate transient response of the hypothalamic-pituitary axis to produce ACTH.

Persistent hypoglycemia produced by HC may have negative consequences on neurological development. Therefore is necessary an aggressive approach. The goal is to achieve adequate blood glucose levels (> 60 mg/dl) with intravenously and oral intake. Glucagon can be administered to raise blood glucose (5 ug/kg/hour). The Insulin excess is treated with drugs, being the first choice Diazoxide (5-20 mg/kg/day orally) that keeps the K<sub>ATP</sub> sensitive channels open. If there is no response, it is suggested to treat with somatostatin analogs such as Octreotide (5-35 mcg/kg/day in bolus or continuous subcutaneous infusion).
Other drugs used less frequently are Nifedipine and Silorimus.

Patients who despite fractional feeding and pharmacological therapy, need intravenous glucose to maintain normoglycemia, are considered resistant to medical treatment, and a surgical solution should be considered. Hussain proposes first-line surgical management in focal HC and in diffuse HC that does not react to pharmacological treatment, which is crucial to decide the treatment, plan the extension of pancreatic resection and evaluate the prognosis. Recent studies emphasize the contribution of Fluorine 18-L-3,4 Dihydroxyphenylalanine Positron Emission Tomography (18F-DOPA-PET/CT scan) which reports a 96% accuracy in differentiating diffuse or focal disease, making precise the localization of a focal lesion in up to 100% of cases. It should be done when it is verified that the HC is persistent (usually after 1 month of life) and could be overlooked if the genetic study demonstrates diffuse disease.

18F-DOPA is not available in our country. Since the patient responded partially to somatostatin analogues, the study was performed with Gallium 68, which adheres to somatostatin receptors, and showed a focal lesion that helped to plan the extent of pancreatectomy.

Focal lesions can be completely cured with partial pancreatectomy or enucleation, while for diffuse form subtotal resection is suggested, and 85-95% of the pancreatic mass should be removed, although relapses may occur and require reintervention.

The most frequent complications of subtotal surgery are infections in the acute phase, development of Diabetes Mellitus, and deficiency in exocrine pancreatic function in the long term. In a cohort of children with subtotal pancreatectomy for HC, it was reported that up to 60% required maintaining medical treatment because hypoglycemia persisted. The incidence of Diabetes Mellitus was 96% and biochemical exocrine pancreatic insufficiency was 72% at 11 years of follow-up.

With the development of minimally invasive techniques, laparoscopic pancreatic surgery has demonstrated its effectiveness and safety, even better cosmetic result, less postoperative pain and physiological impact on patients and reduced development of postoperative adhesions. The first report of laparoscopic pancreatectomy in a pediatric patient with diffuse disease was published in 2001 and laparoscopic enucleation of focal lesions in 2003. Since then, several pediatric series of laparoscopic HC surgery have been published in English literature. Its efficacy has been shown to be comparable to the classical technique, although it requires advanced skills in laparoscopy because it is an area where dissection is near large vessels, and is more complex if the lesion involves the head of the pancreas. Laparoscopy offers the advantage of an amplified view.
of the image and better visualization of anatomical structures. Given the likelihood that some patients require a reoperation, this should be the choice in the first surgery.

In our patient, the surgery was laparoscopic and with complete resection of the focus. No relapse or development of endocrine or exocrine pancreatic insufficiency should be expected.

In conclusion, HC is a rare disease, but it is the first cause of persistent hypoglycemia in the newborn, and its confrontation must be fast and aggressive. The study should be oriented to discriminate the diffuse and focal forms, having a fundamental role the PET/CT and the use of genetic studies. In focal forms and in hyperinsulinism refractory to medical management, surgery is the treatment of choice and the extent of resection will depend on the clinical stage. Laparoscopic pancreatic surgery in the newborn is feasible and has advantages over the open technique, but should be performed by teams with experience in advanced laparoscopy.

Ethical Responsibilities

Human Beings and animals protection: Disclosure the authors state that the procedures were followed according to the Declaration of Helsinki and the World Medical Association regarding human experimentation developed for the medical community.

Data confidentiality: The authors state that they have followed the protocols of their Center and Local regulations on the publication of patient data.

Rights to privacy and informed consent: The authors have obtained the informed consent of the patients and/or subjects referred to in the article. This document is in the possession of the correspondence author.

Financial Disclosure

Authors state that no economic support has been associated with the present study.

Conflicts of Interest

Authors state that any conflict of interest exists regards the present study.

Acknowledgements

The authors would like to thank Neonatology, Pediatric Surgery and Hepatobiliopancreatic Surgery teams, from the Faculty of Medicine, for their invaluable contributions. Particularly, we acknowledge Dr Khalid Hussain from the Pediatric Endocrinology Department of Great Ormond Street Hospital for Children NHS Trust, Londres, for his assistance in the genetic study.

References